A randomised, double-blind trial comparing ceftobiprole medocaril with ceftriaxone with or without linezolid for the treatment of patients with community-acquired pneumonia requiring hospitalisation

International Journal of Antimicrobial Agents

Volumn 39, Issue 3, 2012, Pages 240-246

  Nicholson, Susan C ^a,i   Welte, Tobias ^b   File Jr , Thomas M ^c   Strauss, Richard S ^d   Michiels, Bart ^e   Kaul, Pratibha ^f   Balis, Dainius ^g   Arbit, Deborah ^g   Amsler, Karen ^g   Noel, Gary J ^g,h  

^a JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c SUMMA HEALTH SYSTEM   (United States)

^d Centocor Research and Development   (United States)

^e JANSSEN RESEARCH FOUNDATION   (Belgium)

^f Medical Service   (United States)

^g JOHNSON AND JOHNSON   (United States)

^h WEILL CORNELL MEDICAL COLLEGE   (United States)

ⁱ NONE   (United States)

Author keywords

Ceftobiprole; Community acquired pneumonia; Streptococcus pneumoniae

Indexed keywords

CEFTOBIPROLE MEDOCARIL; CEFTRIAXONE; LINEZOLID;

ADULT; AGED; ARTICLE; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED STUDY; COUGHING; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HOSPITALIZATION; HUMAN; HYPONATREMIA; INJECTION SITE REACTION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VOMITING;

EID: 84857065297     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2011.11.005     Document Type: Article

References (11)

1. M.J. Fine, T.E. Auble, D.M. Yealy, B.H. Hanusa, L.A. Weissfeld, and D.E. Singer A prediction rule to identify low-risk patients with community-acquired pneumonia N Engl J Med 336 1997 243 250 (Pubitemid 27044625)
2. P.G. Ambrose, S.M. Bhavnani, C.M. Rubino, A. Louie, T. Gumbo, and A. Forrest Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore Clin Infect Dis 44 2007 79 86 (Pubitemid 44968990)
3. D.W. Bratzler, A. Ma, and W. Nsa Initial antibiotic selection and patient outcomes: observations from the National Pneumonia Project Clin Infect Dis 47 Suppl. 3 2008 S193 S201
4. T.P. Meehan, M.J. Fine, H.M. Krumholz, J.D. Scinto, D.H. Galusha, and J.T. Mockalis Quality of care, process, and outcomes in elderly patients with pneumonia JAMA 278 1997 2080 2084 (Pubitemid 28016230)
5. L.A. Mandell, R.G. Wunderink, A. Anzueto, J.G. Bartlett, G.D. Campbell, and N.C. Dean Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults Clin Infect Dis 44 Suppl. 2 2007 S27 S72
6. G.G. Zhanel, A. Lam, F. Schweizer, K. Thomson, A. Walkty, and E. Rubinstein Ceftobiprole: a review of a broad-spectrum and anti-MRSA cephalosporin Am J Clin Dermatol 9 2008 245 254 (Pubitemid 351892372)
7. T.A. Davies, M.G. Page, W. Shang, T. Andrew, M. Kania, and K. Bush Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae Antimicrob Agents Chemother 51 2007 2621 2624 (Pubitemid 47047351)
8. World Medical Organization. Nuremberg Doctors' Trial. Declaration of Helsinki (1964). BMJ 1996;313:1448-9.
9. G.J. Noel, K. Bush, P. Bagchi, J. Ianus, and R.S. Strauss A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections Clin Infect Dis 46 2008 647 655 (Pubitemid 351321545)
10. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; sixteenth informational supplement. Document M100-S16. Wayne, PA: CLSI; 2006.
11. H.M. Lamb, D. Ormrod, L.J. Scott, and D.P. Figgitt Ceftriaxone: an update of its use in the management of community-acquired and nosocomial infections Drugs 62 2002 1041 1089 (Pubitemid 34533763)